EE200200087A - Kompositsioon hepatotsellulaarse kartsinoomi raviks - Google Patents

Kompositsioon hepatotsellulaarse kartsinoomi raviks

Info

Publication number
EE200200087A
EE200200087A EEP200200087A EEP200200087A EE200200087A EE 200200087 A EE200200087 A EE 200200087A EE P200200087 A EEP200200087 A EE P200200087A EE P200200087 A EEP200200087 A EE P200200087A EE 200200087 A EE200200087 A EE 200200087A
Authority
EE
Estonia
Prior art keywords
hepatocellular carcinoma
treatment
composition
docetaxel
mum
Prior art date
Application number
EEP200200087A
Other languages
English (en)
Inventor
Chi Chin-Wen
Lin Heng-Liang
Liu Tsung-Yun
Lui Wing-Yiu
Chau Gar-Yang
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of EE200200087A publication Critical patent/EE200200087A/et
Publication of EE05124B1 publication Critical patent/EE05124B1/et

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200200087A 1999-08-31 2000-08-29 Toimeainena dotsetakseeli v?i selle hdraati sisaldava kompositsiooni kasutamine EE05124B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9920548.6A GB9920548D0 (en) 1999-08-31 1999-08-31 Treatment of hepatocellular carcinoma
PCT/EP2000/008782 WO2001015675A2 (en) 1999-08-31 2000-08-29 Use of docetaxel for treating hepatocellular carcinoma

Publications (2)

Publication Number Publication Date
EE200200087A true EE200200087A (et) 2003-04-15
EE05124B1 EE05124B1 (et) 2009-02-16

Family

ID=10860081

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200087A EE05124B1 (et) 1999-08-31 2000-08-29 Toimeainena dotsetakseeli v?i selle hdraati sisaldava kompositsiooni kasutamine

Country Status (34)

Country Link
US (2) US20030158249A1 (et)
EP (1) EP1214061B1 (et)
JP (1) JP4866522B2 (et)
KR (1) KR100670416B1 (et)
CN (1) CN1174748C (et)
AT (1) ATE269700T1 (et)
AU (1) AU777583B2 (et)
BG (1) BG65913B1 (et)
BR (1) BR0013625A (et)
CA (1) CA2382294C (et)
CZ (1) CZ301378B6 (et)
DE (1) DE60011794T2 (et)
DK (1) DK1214061T3 (et)
EA (1) EA004804B1 (et)
EE (1) EE05124B1 (et)
ES (1) ES2218223T3 (et)
GB (1) GB9920548D0 (et)
HK (1) HK1048944B (et)
HR (1) HRP20020171A2 (et)
HU (1) HU228861B1 (et)
IL (2) IL147489A0 (et)
ME (1) MEP7809A (et)
MX (1) MXPA02002041A (et)
NO (1) NO328527B1 (et)
NZ (1) NZ517604A (et)
PL (1) PL212612B1 (et)
PT (1) PT1214061E (et)
RS (1) RS50148B (et)
SI (1) SI1214061T1 (et)
SK (1) SK286378B6 (et)
TW (1) TW589180B (et)
UA (1) UA72927C2 (et)
WO (1) WO2001015675A2 (et)
ZA (1) ZA200201408B (et)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268619C (zh) * 2003-05-08 2006-08-09 上海迪赛诺化学制药有限公司 多烯紫杉醇三水化合物的制备方法
DE602004020506D1 (de) * 2003-12-12 2009-05-20 Quiral Quimica Do Brasil Verfahren zur herstellung von wasserfreien und hydratisierten pharmazeutischen wirkstoffen (apis); aus diesen hergestellte stabile pharmazeutische zusammensetzungen und anwendungen für diese zusammensetzungen
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
KR101643416B1 (ko) * 2005-08-31 2016-07-27 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조방법
CA2880727C (en) 2005-08-31 2019-05-07 Neil P. Desai Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
WO2009007992A2 (en) * 2007-04-20 2009-01-15 Sun Pharmaceutical Industries Limited Pharmaceutical composition produced by microprecipitation
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
PL2552438T3 (pl) 2010-03-26 2016-12-30 Sposoby leczenia raka wątrobowokomórkowego
SG185389A1 (en) * 2010-05-03 2012-12-28 Teikoku Pharma Usa Inc Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
US8842114B1 (en) 2011-04-29 2014-09-23 Nvidia Corporation System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US20160250177A1 (en) * 2015-02-17 2016-09-01 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2629819B1 (fr) * 1988-04-06 1990-11-16 Rhone Poulenc Sante Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
WO1994016693A1 (en) * 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
US5801029A (en) * 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
FR2742751B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
BR9713661A (pt) * 1996-12-30 2000-10-24 Battelle Memorial Institute Formulação e método para o tratamento de neoplasmas por inalação
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
KR100904931B1 (ko) * 1997-06-27 2009-06-29 아브락시스 바이오사이언스, 엘엘씨 나노 입자 및 그의 제조 방법
AU1146099A (en) * 1997-09-18 1999-04-05 Janssen Pharmaceutica N.V. Fused imidazole derivatives for improving oral bioavailability of pharmaceuticalagents
AU1289899A (en) * 1997-10-31 1999-05-24 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
CA2356929A1 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combonation therapy in the treatment of neoplasia
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
CA2633268A1 (en) * 2005-12-13 2007-06-21 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof

Also Published As

Publication number Publication date
ME00624B (me) 2011-12-20
HK1048944B (zh) 2005-04-22
HUP0203197A3 (en) 2005-01-28
DE60011794D1 (de) 2004-07-29
IL147489A (en) 2006-06-11
MEP7809A (en) 2011-12-20
KR100670416B1 (ko) 2007-01-17
DE60011794T2 (de) 2005-07-14
EE05124B1 (et) 2009-02-16
EP1214061B1 (en) 2004-06-23
US20080045584A1 (en) 2008-02-21
EA200200313A1 (ru) 2002-08-29
IL147489A0 (en) 2002-08-14
WO2001015675A3 (en) 2001-09-20
NZ517604A (en) 2004-04-30
ATE269700T1 (de) 2004-07-15
AU7516800A (en) 2001-03-26
NO20020829L (no) 2002-02-20
NO20020829D0 (no) 2002-02-20
CN1372466A (zh) 2002-10-02
DK1214061T3 (da) 2004-11-01
GB9920548D0 (en) 1999-11-03
TW589180B (en) 2004-06-01
WO2001015675A2 (en) 2001-03-08
ES2218223T3 (es) 2004-11-16
CN1174748C (zh) 2004-11-10
PT1214061E (pt) 2004-09-30
BR0013625A (pt) 2002-05-14
CZ301378B6 (cs) 2010-02-03
HK1048944A1 (en) 2003-04-25
YU11402A (sh) 2005-07-19
HUP0203197A2 (hu) 2003-01-28
PL212612B1 (pl) 2012-10-31
RS50148B (sr) 2009-05-06
ZA200201408B (en) 2003-07-30
PL353198A1 (en) 2003-11-03
CA2382294C (en) 2008-06-03
BG65913B1 (bg) 2010-05-31
BG106460A (bg) 2002-09-30
JP2003508427A (ja) 2003-03-04
EP1214061A2 (en) 2002-06-19
CA2382294A1 (en) 2001-03-08
UA72927C2 (uk) 2005-05-16
HRP20020171A2 (en) 2004-02-29
US20030158249A1 (en) 2003-08-21
AU777583B2 (en) 2004-10-21
CZ2002739A3 (cs) 2002-06-12
EA004804B1 (ru) 2004-08-26
JP4866522B2 (ja) 2012-02-01
KR20020060166A (ko) 2002-07-16
SK2712002A3 (en) 2002-07-02
HU228861B1 (hu) 2013-06-28
NO328527B1 (no) 2010-03-08
SK286378B6 (sk) 2008-08-05
MXPA02002041A (es) 2002-08-20
SI1214061T1 (en) 2004-12-31

Similar Documents

Publication Publication Date Title
EE200200087A (et) Kompositsioon hepatotsellulaarse kartsinoomi raviks
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
GB0223038D0 (en) Therapeutic compounds
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
DE60336664D1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
SE9903759D0 (sv) Pharmaceutically active compounds
ATE478662T1 (de) Arzneilösungen enthaltend modafinilverbindungen
DE60128100D1 (de) Analgetisches arzneimittel
NO20032597D0 (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
EA200700979A1 (ru) Пероральные твердые лекарственные формы, содержащие низкую дозу эстрадиола
SE0203817D0 (sv) New composition
DE60023321D1 (de) Zusammensetzung gegen Coccidiose
AU2016219620A1 (en) Compositions and methods useful for treatment of respiratory illness
UA95094C2 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства
TW200505836A (en) Cyclic sulfonamides for inhibition of gamma-secretase

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20150829